Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Long MSTR Daily Target ETF vs Recursion Pharmaceuticals Inc — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $39.7 (market cap $809.00M), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.6× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Long MSTR Daily Target ETF for 18 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| MSTU | RXRX | |
|---|---|---|
Market Cap | $809.00M | $2.14B |
Volume | 4,577,465 | 30,789,535 |
Sector | Leveraged / Inverse | Health |
52-Week High | $432.00 | $6.79 |
52-Week Low | $14.60 | $2.84 |
Typical Hold Time | 18 Days | 23 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTU trades at $38.33, down 2.84% with bearish technical signals dominating. The stock faces resistance at $40-$43 while finding support at $37-$35 levels. Recent corporate actions include a 10:1 reverse stock split effective August 2026 and a $0.29 dividend declaration. Technical indicators show mixed signals with moving averages bearish but oscillators neutral.
The outlook remains cautious given the bearish technical setup and lack of current fundamental data. Investment opportunity exists if the stock holds above $35 support, but risks include continued technical weakness and absence of recent financial metrics. The reverse split suggests management addressing potential price level concerns.
RXRX trades at $3.95, down 7.49% in the last session, reflecting ongoing volatility. The company reported a net loss of $644.76M in 2025, with a negative net income margin of -961.97%, though recent quarters have shown mixed earnings beats. Technical indicators are bullish overall, with moving averages signaling strength. Strategic partnerships, such as the extended data license with Tempus AI (Business Wire, 2026-09-21), aim to bolster its AI-driven drug discovery platform, but high cash burn remains a concern.
The outlook is cautious; while analyst consensus is 40% buy and 60% hold (MarketBeat, 2026-09-20), the stock faces significant risks from persistent losses and slow revenue growth. Upside potential hinges on pipeline success, but investors must weigh the high valuation (P/S of 37.14) against operational challenges and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
